Hypertension is the most common comorbidity associated with anti-VEGF therapy.466,467 Under hypertensive conditions, disrupted VEGF signaling impairs endothelial dysfunction and alters hemodynamics. This evidence concerns the gene VEGFA and endothelial dysfunction.